Lupin announced the launch of Moxifloxacin Ophthalmic Solution USP, 0.5%, having received an approval from the United States Food and Drug Administration (U. S. FDA) earlier.
The product would be manufactured at Lupin's Pithampur (Unit-II) facility, India.
Moxifloxacin Ophthalmic Solution USP, 0.5% is the AT2-rated generic equivalent of Moxeza of Novartis. It is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of certain organisms.
Moxifloxacin Ophthalmic Solution USP, 0.5% (RLD: Moxeza) had an annual sales of approximately USD 10 million in the U. S. (IQVIA MAT December 2019).
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)